{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:50:42Z","timestamp":1784127042185,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Malignancy-related ascites (MRA) is one of the symptoms causing discomfort in advanced cancer patients. Cell-free and concentrated ascites reinfusion therapy (CART) is one of the palliative treatments widely conducted in Japan only. Methods: A systematic review following a meta-analysis of CART was performed. The efficiency and adverse events were evaluated. Results: A total of 2567 patients and 6013 procedures of CART were identified in this study. The mean volume of MRA collected was 4.29 (95% confidence interval (CI) 3.47\u20135.11) L, and the volume reinfused after concentrating was 0.49 (95% CI 0.39\u20130.60) L. A total of 86.1 (95% CI 77.1\u201395.2) g protein and 42.9 (95% CI 36.0\u201350.0) g albumin was reinfused. The mean time to the next paracentesis was 20.7 (95% CI 15.6\u201325.8) days. The body weight was reduced by 3.38 (95% CI 1.90\u20134.86; p &lt; 0.01) kg, and abdominal circumference was reduced by 7.86 (95% CI 6.58\u20139.14; p &lt; 0.001) cm. Serum albumin increased an average of 0.14 (95% CI \u22120.01\u20130.28; p = 0.07) mg\/dL the day after CART. Abdominal distension, dyspnea, and fatigue were alleviated by 6.0 (95% CI 5.59\u20136.51), 2.66 (95% CI 2.05\u20133.28), and 2.64 (95% CI 1.86\u20133.42) points using a numerical rating scale system ranging from 0 to 10. Overall, 17% (95% CI 0.03\u20130.31%) of patients had improved performance status after CART. Significant body temperature elevation was observed, at an average of 0.4 \u00b0C (95% CI 0.18\u20130.62 \u00b0C). Conclusions: CART might be a safe and effective palliative therapy in MRA and further clinical trials are necessary.<\/jats:p>","DOI":"10.3390\/cancers13194873","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T08:27:44Z","timestamp":1632904064000},"page":"4873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3074-2235","authenticated-orcid":false,"given":"Hao","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tanzawa","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kazahari","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Seki","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Schwab, M. (2009). Acites. Encyclopedia of Cancer, Springer.","DOI":"10.1007\/978-3-540-47648-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/CMAR.S100210","article-title":"Drainage of malignant ascites: Patient selection and perspectives","volume":"9","author":"Stukan","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/0256-4947.55167","article-title":"Management of ascites due to gastrointestinal malignancy","volume":"29","author":"Saif","year":"2009","journal-title":"Ann. Saudi Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: Systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_6","first-page":"CD007794","article-title":"Management of drainage for malignant ascites in gynaecological cancer","volume":"12","author":"Kietpeerakool","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","first-page":"202","article-title":"Optimal Paracentesis Volume for Terminally Ill Cancer Patients With Ascites","volume":"6","author":"Ito","year":"2021","journal-title":"J. Pain Symptom Manag."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.21037\/gs-20-335","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: Systematic review and meta-analysis","volume":"9","author":"Cianci","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.transci.2017.08.018","article-title":"CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites","volume":"56","author":"Ito","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","article-title":"Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs","volume":"12","author":"Kloft","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_13","first-page":"507","article-title":"PRISMA declaration: A proposal to improve the publication of systematic reviews and meta-analyses","volume":"135","author":"Bonfill","year":"2010","journal-title":"Med. Clin."},{"key":"ref_14","unstructured":"(2021, June 30). University Hospital Medical Information Network. Available online: https:\/\/uploaduminacjp\/cgi-open-bin\/ctr_e\/ctr_viewcgi?recptno=R000050886."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00520-017-3980-5","article-title":"Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: A concept-proof study","volume":"26","author":"Hanada","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hanafusa, N., Isoai, A., Ishihara, T., Inoue, T., Ishitani, K., Utsugisawa, T., Yamaka, T., Ito, T., Sugiyama, H., and Arakawa, A. (2017). Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177303"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10147-014-0750-y","article-title":"Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites","volume":"20","author":"Ito","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1744-9987.12863","article-title":"Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy","volume":"24","author":"Ito","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"ref_22","first-page":"2165","article-title":"Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital","volume":"45","author":"Iwaki","year":"2018","journal-title":"Gan Kagaku Ryoho. Cancer Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10147-018-1371-7","article-title":"Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites","volume":"24","author":"Kawata","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3892\/mco.2014.335","article-title":"Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer","volume":"2","author":"Maeda","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/aor.13691","article-title":"Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites","volume":"44","author":"Matsusaki","year":"2020","journal-title":"Artif. Organs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1007\/s00520-020-05401-4","article-title":"Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy","volume":"28","author":"Nagata","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_27","first-page":"1556","article-title":"Cell-Free and Concentrated Ascites Reinfusion Therapy for Malignant Intractable Ascites from Colorectal Cancer","volume":"44","author":"Ohta","year":"2017","journal-title":"Gan Kagaku Ryoho. Cancer Chemother."},{"key":"ref_28","first-page":"301","article-title":"Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis","volume":"35","author":"Togami","year":"2014","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_29","first-page":"2353","article-title":"Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer","volume":"32","author":"Ueda","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/jog.12763","article-title":"Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites","volume":"41","author":"Wang","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ejso.2015.04.013","article-title":"Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S","volume":"41","author":"Yamaguchi","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/jog.14670","article-title":"Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study","volume":"47","author":"Yamamoto","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2214\/ajr.153.6.1309","article-title":"Sonographically guided paracentesis for palliation of symptomatic malignant ascites","volume":"153","author":"Ross","year":"1989","journal-title":"Am. J. Roentgenol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000337246","article-title":"A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites","volume":"82","author":"Jatoi","year":"2012","journal-title":"Oncology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s10147-021-01883-2","article-title":"Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: A post-marketing surveillance study","volume":"26","author":"Ishitani","year":"2021","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:00Z","timestamp":1760166420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":36,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194873"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194873","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}